EGFR and non-small cell lung carcinoma: The first promising results on the predictive value of cfDNA in NSCLC patients were generated through important clinical trials that compared the efficacy of first-generation EGFR TKIs against chemotherapy and included cfDNA analysis, beyond the classic approach of tissue biopsy [143,144].